Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allakos Inc. - Common Stock (NQ:ALLK)

0.3291 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Allakos Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
ALLK Stock Earnings: Allakos Beats EPS for Q2 2024
ALLK stock results show that Allakos beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Allakos Provides Business Update and Reports Second Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
From Allakos Inc.
Via GlobeNewswire
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
From Allakos Inc.
Via GlobeNewswire
ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
ALLK stock results show that Allakos met analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
ALLK stock results show that Allakos missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Where Allakos Stands With Analysts
 
Via Benzinga
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are worth checking out this morning as we dive into all of the biggest news moving shares on Friday! 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We are starting the trading week with a dive into the biggest pre-market stock movers worth keeping tabs on for Monday morning! 
Via InvestorPlace
What 4 Analyst Ratings Have To Say About Allakos
 
Via Benzinga
3 Biotech Stocks to Dump Before They Go to Zero
These biotech stocks to sell are burning through cash at an alarming rate and seem destined for zero, making them prime targets for selling. 
Via InvestorPlace
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
From Allakos Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
From Allakos Inc.
Via GlobeNewswire
Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Gold Down 1%; PNC Financial Posts Upbeat Earnings
U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 350 points on Tuesday. The Dow traded down 0.93% to 37,243.85 while the NASDAQ fell 0.58% to 14,885.45. The... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Crude Oil Edges Lower; Morgan Stanley Posts Upbeat Revenue
U.S. stocks traded mostly lower midway through trading, with the Dow Jones index falling more than 150 points on Tuesday. The Dow traded down 0.46% to 37,421.80 while the NASDAQ fell 0.02% to... 
Via Benzinga
Topics Stocks
Why Is Allakos (ALLK) Stock Down 57% Today?
Allakos stock is falling hard on Tuesday as investors in ALLK react to two of the company's Phase 2 clinical trials failing. 
Via InvestorPlace
Trial Setback: Allakos Drops Lead Skin Disorder Candidate, Cuts Workforce By 50%
Allakos reports disappointing topline data from phase 2 trials for lirentelimab in atopic dermatitis and chronic spontaneous urticaria. Company undergoes restructuring to focus on AK006, extending cash... 
Via Benzinga
Dow Dips 200 Points; Goldman Sachs Earnings Top Views
U.S. stocks traded lower this morning, with the Dow Jones index falling more than 200 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.56% to 37,384.20 while the NASDAQ... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Allakos Announces a Restructuring to Focus on Development of AK006
From Allakos Inc.
Via GlobeNewswire
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
From Allakos Inc.
Via GlobeNewswire
Allakos Analyst Turns Bullish, Sees 'Significant Upside' If Study Results Are Positive
Shares of Allakos Inc (NASDAQ: ALLK) were climbing in early trading on Monday. 
Via Benzinga
Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.